Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: Systematic review and meta-analysis

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S439-S446

  Grassly, Nicholas C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

antibody; efficacy; endgame; eradication; immunogenicity; inactivated poliovirus vaccine; IPV; poliomyelitis; seroconversion

Indexed keywords

NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

AGE; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN CONTENT; CROSS PRESENTATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; EPIDEMIOLOGICAL DATA; FRACTIONAL DOSE; HEALTH CARE POLICY; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGICAL PARAMETERS; INFECTION PREVENTION; META ANALYSIS; OUTCOME ASSESSMENT; POLIOMYELITIS; REVIEW; SEROCONVERSION; SEROTYPE; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREND STUDY; COMPARATIVE STUDY; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; PROCEDURES;

AGE FACTORS; HUMANS; IMMUNIZATION; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED;

EID: 84910649654     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit601     Document Type: Review

References (36)

1. Global Polio Eradicatio n Initiative. Polio eradication and endgame strategic plan 2013-2018. http://bit.ly/1649OwE. Accessed 10 July 2013.
2. World Health Organization. Conclusions and recommendations of the Ad Hoc Advisory Committee on P oliomyelitis Eradication, Geneva, 21-22 September 2004. Wkly Epidemiol Rec 2004; 79:401-8.
3. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, November 2012-conclusions and recommendations. Wkly Epidemiol Rec 2013; 88:1-16.
4. Oliver Wyman Inc. Global post-eradication IPV supply and demand assessment: integrated findings. Commissioned by the Bill & Melinda Gat es Foundation, 2009. http://www.polioeradication.org/Research/PolioPipeline/No4Summer2009/GlobalposteradicationIPV.aspx. Accessed 2 June 2013.
5. Salk J. One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. Rev Infect Dis 1984; 6:S444-50.
6. Plotkin AA, Vidor E. Poliovirus vaccine-inactivated. In: Plotkin SA, Orenstein WA, eds. Vaccines. 4th ed. Philadelphia: Saunders, 2004: 625-49.
7. Vidor E, Meschievitz C, Plotkin S. Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997; 16:312-22.
8. Jain PK, Dutta AK, Nangia S, Khare S, Saili A. Seroconversion following killed polio vaccine in neonates. Indian J Pediatr 1997; 64:511-5.
9. Resik S, Tejeda A, Sutter RW, et al. Priming after a fractional dose of inactivated poliovirus vaccine. New Engl J Med 2013; 368:416-24.
10. Mohammed AJ, AlAwaidy S, Bawikar S, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010; 362: 2351-9.
11. Resik S, Tejeda A, Lago PM, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010; 201: 1344-52.
12. Wahid R, Cannon MJ, Chow M. Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio. J Virol 2005; 79:5988-95.
13. Hammon WM, Coriell LL, Ludwig EH, et al. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 5. Reanalysis of results based on laboratory-confirmed cases. J Am Med Assoc 1954; 156:21-7.
14. Salk D, Vanwezel AL, Salk J. Induction of long-term immunity to paralytic poliomyelitis by use of non-infectious vaccine. Lancet 1984; 2: 1317-21.
15. Swartz TA, Handsher R, Stoeckel P, et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989; 5:143-5.
16. Salk J, Stoeckel P, Vanwezel AL, Lapinleimu K, Vansteenis G. Antigen content of inactivated poliovirus vaccine for use in a one-dose or 2-dose regimen. Ann Clin Res 1982; 14:204-12.
17. Bottiger M. Polio immunity to killed vaccine-An 18-year follow-up. Vaccine 1990; 8:443-5.
18. Faden H, Duffy L, Sun M, Shuff C. Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-pote ncy inactivated trivalent poliovirus vaccines. J Infect Dis 1993; 168:452-4.
19. Bottiger M. Antibody stimulation in individuals without demonstrable poliovirus antibodies following a fifth injection of inactivated poliovirus vaccine. Acta Path Micro Im B 1973; B81:795-8.
20. Rumke HC, Oostvogel PM, Vansteenis G, Vanloon AM. Poliomyelitis in the Netherlands-Areviewofpopulationimmunityandexposurebetween the epidemics in 1978 and 1992. Epidemiol Infect 1995; 115:289-98.
21. Abbink F, Buisman AM, Doornbos G, Woldman J, Kimman TG, Conyn-van Spaendonck MA. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005; 191:990-9.
22. Salk JE. How many injections of poliomyelitis vaccine for effective and durable immunity. J Am Med Assoc 1958; 167:1-7.
23. Salk JE. Persistence of imm unity after administration of formalintreated poliovirus vaccine. Lancet 1960; 2:715-23.
24. Salk J. Future prospects for vaccination against virus diseases. Behring Institute Mitteilungen 1982; 71:34-42.
25. Salk JE. Requirements for persistent immunity to poliomyelitis. Trans Assoc Am Physicians 1956; 69:105-14.
26. Estivariz CF, Molnar Z, Venczel L, et al. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. Am J Epidemiol 2011; 174:316-25.
27. Kapusinszky B,Molnar Z,Szomor KN,Berencsi G. Molecular characterization of poliovirus isolates from children who contracted vaccineassociated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. FEMS Immunol Med Microbio l 2010, 58, 211-7.
28. Robertson SE, Drucker JA, Fabreteste B, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988; 331: 897-9.
29. Clark A, Sanderson C. Timing of children's vaccinations in 45 lowincome and middle-income countries: an analysis of survey data. Lancet 2009; 373:1543-9.
30. Akmatov MK, Mikolajcz yk RT. Timeliness of childhood vaccinations in 31 lowand middle-income countries. J Epidemiol Community Health 2012; 66:e14.
31. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiven ess of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. J Am Med Assoc 1996; 276:967-71.
32. Simoes EA, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibodyresponse of infants to 2 doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 1985; 139:977-80.
33. Dayan GH, Thorley M, Yamamura Y, et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007; 195: 12-20.
34. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996; 14:735-46.
35. Hird TR, Grassly NC. Systematic rev iew of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012; 8: e1002599.
36. Mangal TD, Aylward RB, Grassly N C. The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting. Am J Epidemiol 2013; 178:1579-87.